1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Medivir AB

Medivir AB

MVIR.ST
Medivir ABSE flagStockholm Stock Exchange
1.88
SEK
+0.00
- -
1.18BMarket Cap
Medivir AB
MVIR.ST
(Stockholm Stock Exchange)

Recent

price

1.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.49
15.7
3.67
9.6
38.03
10.98
2.32
1.12
0.67
0.24
0.39
0.4
0.08
0.13
0.03
0.06
0.04
Revenue per Share
-3.65
2.56
-4.72
-0.46
24.38
1.74
7.06
-11.03
-9.84
-3.42
-1.18
-0.98
-1.59
-1.48
-1.08
-0.66
-0.39
Basic EPS, GAAP
-2.25
0.9
-3.11
0.92
21.59
7.81
-6.95
-11.39
-9.14
-4.15
-1.68
-0.76
-1.83
-0.99
-1.09
-0.51
-0.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
23.58
18.96
18.48
42.96
36.62
43.63
17.16
8.52
5.11
3.93
4.13
2.83
2.09
1.03
0.35
0.35
Book Value per Share
- -
12.2
7.81
9.11
33.91
26.57
40.82
13.4
5.84
2.44
1.26
2.72
1.42
1.16
0.17
0.2
0.23
Tangible Book Value per Share
37
44
46
46
46
43
40
33
36
36
36
64
56
60
114
143
234
Basic Weighted Avg Shares
55
699
171
446
1,767
474
93
37
24
9
14
26
4
8
3
9
9
Sales/Revenue/Turnover
-248.99
16.01
-117.98
5.64
67.27
11.69
-335.73
-990.29
-1,471.02
-1,474.03
-399.23
-252.19
-2,010.16
-1,214.99
-3,675.98
-1,092.98
-1,006.74
Operating Margin (%)
8
23
35
33
33
40
33
30
26
7
4
3
3
3
3
33
33
Depreciation Expense
-134
114
-219
-21
1,133
75
283
-360
-350
-123
-43
-63
-89
-89
-123
-94
-90
Net Income, GAAP
- -
- -
- -
42.05
5.03
31.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-244.44
16.28
-128.38
-4.78
64.11
15.83
304
-983.15
-1,468.02
-1,414.95
-305.56
-247.19
-2,013.73
-1,170.06
-3,539.52
-1,109.8
-1,016.85
Profit Margin (%)
559
514
316
379
1,536
1,026
1,598
387
215
98
44
184
95
121
18
90
124
Working Capital
- -
70
40
40
- -
- -
- -
- -
- -
37
15
13
13
11
9
6
- -
LT Debt
607
1,096
875
853
1,983
1,450
1,733
514
308
184
142
281
193
218
116
155
191
Total Equity
- -
- -
- -
1.57
77.2
2.17
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
-2.17
77.81
4.69
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-35.27
13.36
-22.24
-2.47
79.91
4.37
17.77
-32.06
-85.27
-50.17
-26.12
-29.84
-37.46
-43.5
-73.97
-69.74
-61.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
3
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
6
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
449
539
Market Capitalization
179
184
1,336

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
27
124
153
Cash, Cash Equivalents & STI
24
119
149
Accounts Receivable, Net
4
- -
4
Inventories
- -
- -
- -
Total Current Liabilities
59
34
29
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.7%
13.42%
34.37%
Free Cash Flow
-16.01%
22.98%
-40.94%
Net Income, GAAP
2.03%
20.79%
-23.45%
Sales/Revenue/Turnover
-1.61%
32.66%
144.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
1
1
3
2025
1
2
1
6
9
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.23
-0.32
-0.3
-0.23
-1.08
2025
-0.12
-0.2
-0.13
-0.19
-0.66
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Human Metabolome Technologies, Inc. (6090.T)
B&K Corporation Limited (2396.HK)
LabTurbo Biotech Corporation (7725.TWO)
Clearside Biomedical, Inc. (CLSD)
Greenyn Biotechnology Co., Ltd (6846.TWO)
Propanc Biopharma, Inc. (PPCB)
Business
Medivir AB is a Swedish specialty pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for underserved indications in oncology and infectious diseases. The company develops targeted antiviral and oncology programs, including protease inhibitors and other novel modalities, and collaborates with partners to advance clinical candidates through late-stage development and potential commercialization. Medivir’s portfolio emphasizes out-licensing and partnerships to monetize research results while maintaining selective internal development capacity. Main products and services: research and development of pharmaceutical compounds for oncology and infectious diseases; preclinical and clinical development services; strategic collaborations and licensing of product candidates; go-to-market partnerships with pharmaceutical or biotech partners; risk-sharing development programs; manufacturing support and process development activities for clinical supplies; regulatory strategy and submission support; pharmacovigilance and safety monitoring services for partnered programs. Latest major company changes: enters strategic partnerships and license agreements to advance pipeline candidates; pursues collaborations for late-stage development and commercialization rights; announces platform and program updates including new clinical trial initiations or expansions; reorganizations to optimize R&D focus and capital deployment; engages in potential funding rounds or financing arrangements to support advanced programs; announces changes in leadership roles or board composition as part of strategic realignment. Additional context: operates in the biopharmaceutical industry with a focus on oncology and infectious disease therapeutic areas; targets global markets, prioritizing Europe and the United States; founded in 1994 and headquartered in Stockholm, Sweden; maintains collaboration or subsidiary structures with partner companies and may participate in joint ventures to develop and commercialize drug candidates.